CSL LTD SPON.ADR 2 (CSJA F) stock market data APIs
€56.7899
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
CSL LTD SPON.ADR 2 Financial Data Overview
Price chart is built with
Anychart
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Prev. Close
56.7899
Open
56.7899
High
56.7899
Low
56.7899
52 wk Range
55.8159-90.6868
Market Cap
57 560 M
P/E Ratio
21.8631
Shares Outstanding
970 M
Revenue
15 558 M
Dividends (Yield)
0.0517
Beta
0.256
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL LTD SPON.ADR 2 data using free add-ons & libraries
Get CSL LTD SPON.ADR 2 Fundamental Data
CSL LTD SPON.ADR 2 Fundamental data includes:
- Net Revenue: 15 558 M
- EBITDA: 4 909 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL LTD SPON.ADR 2 News
New
CSL Full Year 2025 Earnings: Misses Expectations
Explore CSL's Fair Values from the Community and select yours CSL (ASX:CSL) Full Year 2025 Results Key Financial Results Revenue: US$15.6b (up 5.1% from FY 2024). Net income: US$3.00b (up 14% from ...
CSL to spin off flu vaccine arm and cut 15% workforce; annual profit rises
(Reuters) -Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a st...
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores th...
Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
Company Logo The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. Th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
